265.4

-0.56%↓

SAN

86.04

-0.65%↓

MRK1

108.6

+0.51%↑

SHL.DE

47.41

-0.34%↓

ARGX

587

-3.55%↓

265.4

-0.56%↓

SAN

86.04

-0.65%↓

MRK1

108.6

+0.51%↑

SHL.DE

47.41

-0.34%↓

ARGX

587

-3.55%↓

265.4

-0.56%↓

SAN

86.04

-0.65%↓

MRK1

108.6

+0.51%↑

SHL.DE

47.41

-0.34%↓

ARGX

587

-3.55%↓

265.4

-0.56%↓

SAN

86.04

-0.65%↓

MRK1

108.6

+0.51%↑

SHL.DE

47.41

-0.34%↓

ARGX

587

-3.55%↓

265.4

-0.56%↓

SAN

86.04

-0.65%↓

MRK1

108.6

+0.51%↑

SHL.DE

47.41

-0.34%↓

ARGX

587

-3.55%↓

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Suletud

7.19 -2.97

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.01

Max

7.82

Põhinäitajad
By Trading Economics
Sissetulek	-46M
Müük	-21M
Kasumimarginaal	221.361
Töötajad	108
EBITDA	-38M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+35.87% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	17. sept 2025

Turustatistika
By TradingEconomics
Turukapital	380M
Eelmine avamishind	10.16
Eelmine sulgemishind	7.19

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. aug 2025, 22:51 UTC

Tulu

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27. aug 2025, 23:57 UTC

Tulu

Trip.com Group 1H Rev $4.01B

27. aug 2025, 23:57 UTC

Tulu

Trip.com Group 1H Adj EPS $1.84

27. aug 2025, 23:57 UTC

Tulu

Trip.com Group 1H EPS $1.82

27. aug 2025, 23:50 UTC

Market Talk

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27. aug 2025, 23:39 UTC

Tulu

Correction to Nvidia Earnings Article -- WSJ

27. aug 2025, 22:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. aug 2025, 22:59 UTC

Market Talk

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27. aug 2025, 22:58 UTC

Tulu

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27. aug 2025, 22:57 UTC

Tulu

South32 FY Free Cash Flow $192 Million

27. aug 2025, 22:56 UTC

Tulu

South32 FY Total Capital Expenditure $1.35 Billion

27. aug 2025, 22:56 UTC

Tulu

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27. aug 2025, 22:55 UTC

Tulu

South32 Net Cash $123 Million at June 30

27. aug 2025, 22:54 UTC

Tulu

South32: Focused on Maintaining Strong Operating Momentum

27. aug 2025, 22:53 UTC

Tulu

South32: $144 Million Remains to be Returned to Shareholders Under Program

27. aug 2025, 22:53 UTC

Tulu

South32 Extends Capital Management Program for 12 Months

27. aug 2025, 22:52 UTC

Tulu

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27. aug 2025, 22:51 UTC

Tulu

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27. aug 2025, 22:51 UTC

Tulu

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27. aug 2025, 22:50 UTC

Tulu

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27. aug 2025, 22:50 UTC

Tulu

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27. aug 2025, 22:45 UTC

Tulu

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27. aug 2025, 22:44 UTC

Tulu

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27. aug 2025, 22:44 UTC

Tulu

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27. aug 2025, 22:43 UTC

Tulu

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27. aug 2025, 22:43 UTC

Tulu

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27. aug 2025, 22:42 UTC

Tulu

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27. aug 2025, 22:42 UTC

Tulu

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27. aug 2025, 22:40 UTC

Tulu

Sandfire Resources Net Debt $123 Million at June 30

27. aug 2025, 22:40 UTC

Tulu

Sandfire Resources FY Underlying Ebitda $527.7 Million

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

35.87% tõus

12 kuu keskmine prognoos

Keskmine 10 EUR 35.87%

Kõrge 10 EUR

Madal 10 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.